AHMEDABAD: Zydus Cadila group will be making an oral presentation on Saroglitazar, a novel compound under development for treatment in Non-alcoholic Steatohepatitis (NASH), at the Keystone Symposium on Liver Metabolism and Non-alcoholic Fatty Liver ... Times of India, 3 weeks ago
Cadila Healthcare intimates presentation of Saroglitazar for treatment of NASH - Business Standard India, 3 weeks ago
Zydus to present data from Saroglitazar to treat NASH at Keystone Symposium - PharmaBiz, 3 weeks ago
1 images for "zydus group cadila healthcare"
Ahmedabad: The Torrent group and Cadila Healthcare were among the top donors from Gujarat to have made donations to Congress and NCP ahead of 2014 Lok Sabha elections, a report by advocacy group Association for Democratic Reforms (ADR) said. The ...4 Traders, 2 months ago Zydus, Torrent among top donors to Cong, NCP in 2014 elections Hindu Business Line, 2 months ago Torrent Group & Cadila Healthcare among top political donors from Gujarat during 2013-14 Indian Express, 2 months ago Torrent Group, Cadila Healthcare among top political donors from Gujarat; BJP only defaulter Financial Express, 2 months ago
Firstcall Research's report on Cadila Healthcare For the 3rd quarter ended Dec 31st, 2014, Zydus Cadila reported Net sales of Rs 21894.60 mn, up by 16.98% from Rs. 18716.90 mn in the corresponding quarter of the previous year on a consolidated ...Moneycontrol.com, 1 week ago Buy Cadila Healthcare; target of Rs 1715: Firstcall Moneycontrol.com, 2 months ago
For the third quarter ended 31st December 2014, Cadila Healthcare Limited registered a Net Profit of Rs. 282 crores, up by 52% from Rs. 186 crores in the corresponding period last year. The company registered a Total Income from Operations of Rs.FiercePharma, 2 weeks ago
Cadila Healthcare, a Rs. 7,200 crore pharma major from Ahmedabad, has posted impressive financial performance during the third quarter ended December 2014 and its consolidated net profit went up sharply by 51.6 per cent to Rs. 282 crore from Rs. 186 ...PharmaBiz, 2 weeks ago Cadila Healthcare bucks trend on strong Q3 earnings Capital Market, 3 weeks ago
dia | New Delhi January 8, 2015 Last Updated at 18:45 IST Drug firm Cadila Healthcare is voluntarily recalling 19,536 bottles of benzonatate capsules, used to treat coughs, in the US due to "wet and/or leaking capsules". According to a notification ...Business Standard India, 1 month ago Cadila Healthcare recalls 19,536 bottles of cough treatment drug in US Economic Times, 1 month ago
More from: , Smart Investor...and 1 other sources
Cadila Healthcare is currently trading at Rs. 1705.65, up by 59.40 points or 3.61% from its previous closing of Rs. 1646.25 on the BSE. The scrip opened at Rs. 1662.35 and has touched a high and low of Rs. 1717.95 and Rs. 1662.35 respectively. So ...Arihant Capital, 1 month ago
Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies
Details Category: Small Molecules Published on Monday, 16 February 2015 12:51 Hits: 46 ZYAN1 is an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, designed to increase the natural production of erythropoietin ...PipelineReview, 2 weeks ago Zydus begins Phase - III study of Saroglitazar in NASH, a liver disease caused by obesity, diabetes and lipid disorders PipelineReview, 1 month ago
Secondary private equity transactions seem to be on the rise in India's healthcare space. Capital International, a global private equity (PE) fund, is learnt to be in talks to acquire a 11 per cent stake in Delhi-based Mankind Pharma for Rs ...Business Standard India, 2 weeks ago
Gujarat has done very well in some sectors but with its health indicators still lagging behind, will it be the blueprint for the rest of India? By Raelene Kambli Sickle Cell Anemia Control Programme Gujarat's model of development has been ...Financial Express, 1 month ago
on your WebpageAdd Widget >Get your members hooked!